CELEX: 62015TA0678
Language: en
Date: 2016-12-15 00:00:00
Title: Joined Cases T-678/15 and T-679/15: Judgment of the General Court of 15 December 2016 — Novartis v EUIPO (Representation of a grey curve and representation of a green curve) (EU trade mark — Applications for EU figurative trade marks representing a grey curve and representing a green curve — Absolute ground for refusal — Distinctive character — Simplicity of the sign — Article 7(1)(b) of Regulation (EC) No 207/2009)

6.2.2017   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 38/32
            
         Judgment of the General Court of 15 December 2016 — Novartis v EUIPO (Representation of a grey curve and representation of a green curve)
   (Joined Cases T-678/15 and T-679/15) (1)
   
   ((EU trade mark - Applications for EU figurative trade marks representing a grey curve and representing a green curve - Absolute ground for refusal - Distinctive character - Simplicity of the sign - Article 7(1)(b) of Regulation (EC) No 207/2009))
   (2017/C 038/44)
   Language of the case: English
   
      Parties
   
   
      Applicant: Novartis AG (Basel, Switzerland) (represented by: M. Zintler, lawyer)
   
      Defendant: European Union Intellectual Property Office (represented by: H. Kunz and S. Hanne, Agents)
   
      Re:
   
   Two actions brought against the decisions of the Fifth Board of Appeal of EUIPO of 23 September 2015 (Cases R 78/2015-5 and R 89/2015-5), concerning applications for registration of two figurative signs, representing a grey curve and representing a green curve, as EU trade marks.
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Annuls the decisions of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 23 September 2015 (Cases R 78/2015-5 and R 89/2015-5);
            
         
               2.
            
            
               Allows the appeals brought by Novartis AG before that Board of Appeal;
            
         
               3.
            
            
               Orders EUIPO to pay the costs.
            
         
      (1)  OJ C 90, 7.3.2016.